Chemours sees Q2 revenue growth low to mid-teens sequentially

In the second quarter, the Company anticipates consolidated Net Sales to increase in the low to mid-teens sequentially, with consolidated Adjusted EBITDA also expected to increase within a range of 40% to 45%. Corporate Expenses, as an offset to Adjusted EBITDA, are expected to decrease in the low single-digits compared with the first quarter. The Company also anticipates free cash flow in the second quarter to be slightly positive, paired with capital expenditures in the range of $50 million.